Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Clinical Trials Clinical Trials 104

Delveinsight

DECEMBER 23, 2020

As per the Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful. What are the most common food allergies? Egg Allergy.

Allergies 52

Allergies Immune Response Antibody Protein 52

Scienmag

APRIL 19, 2021

A study of immune cells circulating in the blood hints the gut’s immune response to COVID-19 infection may not provide sufficient whole-body immunity from the virus Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study (..)

Immune Response 74

Immune Response Allergies Medicine Vaccination 74

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Intravacc has received a contract worth $14.6m Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. Members of the task force say that individuals with common allergies to medications, foods, inhalants, insects, and latex are no more likely than the general public to have an allergic reaction to the Pfizer-BioNTech COVID-19 vaccine. FRIDAY, Dec.

Allergies 52

Allergies Vaccination Vaccine Immune Response 52

Drug Discovery World

SEPTEMBER 25, 2023

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response. “An

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 8, 2023

The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses. The samRNA is delivered in a lipid nanoparticle (LNP) formulation.

Vaccination 130

Vaccination Vaccine Clinical Trials Clinical Trials 130

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

Scienmag

JANUARY 22, 2021

Results suggest lasting immunity after infection In a promising result for the success of vaccines against COVID-19, rhesus macaque monkeys infected with the human coronavirus SARS-CoV-2 developed protective immune responses that might be reproduced with a vaccine.

Immune Response 40

Immune Response Development Vaccination Vaccine 40

Scienmag

JUNE 3, 2021

A University of Birmingham-led study funded by the UK Coronavirus Immunology Consortium has found that many patients with COVID-19 produce immune responses against their body’s own tissues or organs. COVID-19 has been associated with a variety of unexpected symptoms, both at the time of infection and for many months afterwards.

Immune Response 40

Immune Response Allergies Medicine 40

Scienmag

SEPTEMBER 8, 2020

Immune responses to SARS-CoV-2 may depend on viral load and infection time course COVID-19 (SARS-CoV-2) infections tend to be more severe among older adults and males, yet the mechanisms underlying increased mortality in these two demographics are unknown.

Immune Response 40

Immune Response Gerontology Allergies Medicine 40

Drug Discovery World

JANUARY 20, 2023

Janssen Vaccines & Prevention sponsored the Mosaico study with funding support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. No safety issues In its scheduled data review, the DSMB determined there were no safety issues with the experimental vaccine regimen.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) In addition, the T-cell responses are especially strong and stable over time, which is also potentially important for activity against these variants.”.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 1, 2023

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

MARCH 10, 2021

Immune cells specialize to ensure the most efficient defense against viruses and other pathogens. Researchers at the University of Basel have shed light on this specialization of T cells and shown that it occurs differently in the context of an acute and a chronic infection.

Immune Response 49

Immune Response Research Allergies Medicine 49

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccination 52

Vaccination Vaccine Immune Response Allergies 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The Janssen vaccines studied in the Imbokodo and Mosaico studies were based on the mosaic concept, where they were intentionally designed to include a broader immunogen that could be used everywhere, says Dr. Mary Marovich, director of the Vaccine Research Program at National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Delveinsight

AUGUST 6, 2020

By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. FDA turns back peanut allergy patch of DBV Technologies. A peanut allergy patch which is based on new delivery technology has hit a snag at the FDA. The agency raised no safety concerns.

Allergies 53

Allergies Gene Therapy Vaccination Vaccine 53

Drug Discovery World

MARCH 23, 2023

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID) and led by Mark M Davis, Director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in California.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease.

Immune Response 52

Immune Response Research Clinical Trials Clinical Trials 52

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

The Pharma Data

OCTOBER 29, 2021

Johnson & Johnson’s Ebola vaccine authority originates from a cooperative exploration program with the NIH and entered direct backing and preclinical services from the National Institute of Allergy and Infectious Conditions, part of NIH, under Contract Number HHSN272200800056C.

Immune Response 40

Immune Response Medicine Vaccination Vaccine 40

Drug Discovery World

FEBRUARY 3, 2023

One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. The fact that four control animals got sick demonstrates that pre-existing immunity to EBOV and VSV-EBOV has limited effect on protection from SUDV.

Vaccination 52

Vaccination Vaccine Protein Genetic Engineering 52

Scienmag

APRIL 12, 2021

BOSTON – Exercise training may slow tumor growth and improve outcomes for females with breast cancer – especially those treated with immunotherapy drugs – by stimulating naturally occurring immune mechanisms, researchers at Massachusetts General Hospital (MGH) and Harvard […].

Immune Response 41

Immune Response Drugs Research Allergies 41

pharmaphorum

NOVEMBER 8, 2021

The results suggest that the REGEN-COV (casirivimab/imdevimab) antibody could play a key role in protecting people who do not mount a sufficiently strong immune response after COVID-19 vaccines, according to the company.

Antibody 105

Antibody Vaccination Vaccine Immune Response 105

XTalks

NOVEMBER 6, 2020

Related: Red Meat Allergy Test Gets FDA Clearance. “We Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Scienmag

MARCH 25, 2021

Cell Stem Cell, 2021, HOUSTON, TX – March 25, 2021 – Humans are born with tens of thousands of hematopoietic stem cells (HSCs) that collectively ensure lifelong production of blood and immune cells that protect us from infections. Credit: Hormaechea-Agulla et al.,

Immune Response 52

Immune Response Production Allergies Medicine 52

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Antibody 52

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 1, 2020

The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

Vaccination 69

Vaccination Vaccine Trials Clinical Trials 69

Scienmag

AUGUST 21, 2020

Credit: Markus Marcetic Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19.

Immune Response 52

Immune Response Research Allergies Medicine 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Posted: December 2020.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Investigators aim to have initial findings available by August 2022.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Scienmag

OCTOBER 1, 2020

Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Immune Response 40

Immune Response Research Allergies Vaccination 40

The Pharma Data

JANUARY 9, 2021

While reactions to vaccines are extremely rare, the American College of Allergy, Asthma and Immunology (ACAAI) said anyone being vaccinated should be asked if they have a history of a severe allergic reaction to an injectable medication. But such patients should be warned of the possibility that they will have a lower immune response.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Scienmag

SEPTEMBER 15, 2020

Scientists will study how SARS-CoV-19 hijacks the immune system and creates a ‘cytokine storm’ Credit: Sanford Burnham Prebys Medical Discovery Institute.

Immune Response 60

Immune Response Drugs Scientist Allergies 60